Clinical outcomes for anti-CD19 CAR T cell (CTL019) products not meeting commercial release specifications
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.03.011
Abstract: Background & Aim Background: Tisagenlecleucel (CTL019) is approved for treatment of relapsed/refractory (r/r) aggressive B-cell lymphomas after second line therapy. Prior to CTL019 release for commercial use in the United States, the final manufactured, patient-specific… read more here.
Keywords: ctl019; release specifications; ctl019 products; cell ... See more keywords
Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131123
Abstract: Objectives: Tisagenlecleucel (CTL019) is a chimeric antigen receptor T cell- therapy that reprograms autologous T cells to target CD19+ leukemia cells, approved in the US (2017) and in the EU (2018). This study reports the… read more here.
Keywords: cell acute; infusion; safety efficacy; ctl019 ... See more keywords
The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.1330.1330
Abstract: Introduction : Pediatric B-cell acute lymphoblastic leukemia (pALL) affects approximately 400 new patients in the United Kingdom (UK) each year (Pediatric Blood & Cancer 2017;00:e26615). With current therapies, approximately 80% of patients achieve remission; however… read more here.
Keywords: value; ctl019; consumer; novartis pharmaceuticals ... See more keywords
Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3181.3181
Abstract: The adoptive transfer of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19 has shown remarkable activity for patients with B cell malignancies. Using a second- generation CAR signaling through… read more here.
Keywords: employment; car; ctl019; research funding ... See more keywords
Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.609.609
Abstract: Introduction: CTL019 (tisagenlecleucel) is a chimeric antigen receptor T-cell therapy (CAR-T)for the treatment of relapsed or refractory (r/r) pediatric/young adult patients (pts) with B-cellacute lymphoblastic leukemia(ALL). Current treatments for r/r pediatric ALL (pALL) include clofarabine… read more here.
Keywords: treatment; ctl019; clo; cost effectiveness ... See more keywords
Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.10523
Abstract: 10523Background: The global ELIANA trial (NCT02435849) evaluates the efficacy and safety of CTL019, a single infusion of genetically modified autologous chimeric antigen receptor–expressing T cells targeting CD19+ cells in pediatric and young adult r/r B-ALL… read more here.
Keywords: young adult; following ctl019; infusion; pediatric young ... See more keywords